TQS-168 showed increased median survival and decreased pro-inflammatory cytokines and inflammatory monocytes in a widely used SOD1-G93A transgenic mouse model and demonstrated a similar decrease ...

"This is an important milestone for Tranquis as we initiate clinical development of TQS-168, a novel PGC1a modulator that offers great potential as a new class of treatment for ALS patients and a ...